CAMBRIDGE, Mass – September 22, 2014 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company has been named by FierceBiotech as one of 2014’s Fierce 15, designating it as one of the most promising private biotechnology companies in the industry. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position. The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech’s twelfth annual Fierce 15 selection. A complete list of “Fierce 15” companies can be found online at www.fiercebiotech.com/fierce15.
“After a long dry spell, antibiotics R&D is beginning to make a comeback, and Spero hopes to be on the cutting edge,” says John Carroll, editor of FierceBiotech. “This biotech is part of a large crop of startups being shepherded at Atlas Venture. Partnered with Roche, which has helped foster this company, Atlas Venture Partner Ankit Mahadevia has brought together a big team of experts to focus on some new ideas. And they’re demonstrating just how much early potential a virtual company can have as it sets out to build a pipeline.”
“Spero is honored to be chosen by the editors of FierceBiotech as one of this year’s Fierce 15 – a welcomed acknowledgement of our company’s innovative and creative approach to anti-infective drug development in a new era for the field,” said Ankit Mahadevia, M.D., Venture Partner at Atlas Venture and Spero’s President.
About Fierce Biotech
FierceBiotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 270,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.
Spero is a product-focused biopharmaceutical company developing a pipeline of novel treatments for bacterial infections and is located in Cambridge, Massachusetts. Spero’s MvfR inhibitor program works differently from existing antibiotics by targeting a pathway involved in two critical bacterial processes: virulence and persistence. Spero’s pipeline of drug candidates may uniquely reduce the morbidity caused by severe infections and promote their clearance, including in bacterial strains highly resistant to even the most potent existing antibiotics. For more information, please visit www.sperotherapeutics.com.
Ankit Mahadevia, M.D.
Venture Partner at Atlas Ventures
Maureen L. Suda (Media)
Suda Communications LLC